Your browser doesn't support javascript.
loading
Genomic landscape of TP53 -mutated myeloid malignancies.
Abel, Haley J; Oetjen, Karolyn A; Miller, Christopher A; Ramakrishnan, Sai M; Day, Ryan B; Helton, Nichole M; Fronick, Catrina C; Fulton, Robert S; Heath, Sharon E; Tarnawsky, Stefan P; Srivatsan, Sridhar Nonavinkere; Duncavage, Eric J; Schroeder, Molly C; Payton, Jacqueline E; Spencer, David H; Walter, Matthew J; Westervelt, Peter; DiPersio, John F; Ley, Timothy J; Link, Daniel C.
Afiliação
  • Abel HJ; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Oetjen KA; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Miller CA; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Ramakrishnan SM; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Day RB; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Helton NM; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Fronick CC; McDonnell Genome Institute, Washington University School of Medicine.
  • Fulton RS; McDonnell Genome Institute, Washington University School of Medicine.
  • Heath SE; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Tarnawsky SP; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Srivatsan SN; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Duncavage EJ; Department of Pathology & Immunology, Washington University School of Medicine.
  • Schroeder MC; Department of Pathology & Immunology, Washington University School of Medicine.
  • Payton JE; Department of Pathology & Immunology, Washington University School of Medicine.
  • Spencer DH; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Walter MJ; McDonnell Genome Institute, Washington University School of Medicine.
  • Westervelt P; Department of Pathology & Immunology, Washington University School of Medicine.
  • DiPersio JF; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Ley TJ; Division of Oncology, Department of Medicine, Washington University School of Medicine.
  • Link DC; Division of Oncology, Department of Medicine, Washington University School of Medicine.
medRxiv ; 2023 Jan 11.
Article em En | MEDLINE | ID: mdl-36711871
ABSTRACT
TP53 -mutated myeloid malignancies are most frequently associated with complex cytogenetics. The presence of complex and extensive structural variants complicates detailed genomic analysis by conventional clinical techniques. We performed whole genome sequencing of 42 AML/MDS cases with paired normal tissue to characterize the genomic landscape of TP53 -mutated myeloid malignancies. The vast majority of cases had multi-hit involvement at the TP53 genetic locus (94%), as well as aneuploidy and chromothripsis. Chromosomal patterns of aneuploidy differed significantly from TP53 -mutated cancers arising in other tissues. Recurrent structural variants affected regions that include ETV6 on chr12p, RUNX1 on chr21, and NF1 on chr17q. Most notably for ETV6 , transcript expression was low in cases of TP53 -mutated myeloid malignancies both with and without structural rearrangements involving chromosome 12p. Telomeric content is increased in TP53 -mutated AML/MDS compared other AML subtypes, and telomeric content was detected adjacent to interstitial regions of chromosomes. The genomic landscape of TP53 -mutated myeloid malignancies reveals recurrent structural variants affecting key hematopoietic transcription factors and telomeric repeats that are generally not detected by panel sequencing or conventional cytogenetic analyses. Key Points WGS comprehensively determines TP53 mutation status, resulting in the reclassification of 12% of cases from mono-allelic to multi-hit Chromothripsis is more frequent than previously appreciated, with a preference for specific chromosomes ETV6 is deleted in 45% of cases, with evidence for epigenetic suppression in non-deleted cases NF1 is mutated in 48% of cases, with multi-hit mutations in 17% of these cases TP53 -mutated AML/MDS is associated with altered telomere content compared with other AMLs.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: MedRxiv Ano de publicação: 2023 Tipo de documento: Article